Acquisition of Apollo

RNS Number : 6568P

Assura PLC

19 February 2021

 

19 February 2021

Assura plc

Acquisition of Apollo to further strengthen development pipeline and capability

Assura plc ("Assura" or "the Company"), the UK's leading primary care property investor and developer, today announces that it has completed the acquisition of primary care developer Apollo Capital Projects Development Limited ("Apollo").

Apollo has a strong, 20-year track record of developing high-quality primary care properties across the UK, with a very experienced four-person development team. As well as expanding the Assura development team to 11 specialist surveyors, the acquisition increases our immediate and extended development pipeline by an initial eight schemes with an estimated total capital expenditure of £50 million.

In addition, the current live development scheme at Beaconsfield will be converted from a forward-fund to an in-house development.

Jonathan Murphy, CEO, said: "The acquisition of Apollo will further enhance our sector-leading in-house development capabilities and substantially expand our pipeline, which is already the largest in our history.

"Following our acquisition of primary care developer GPI in 2019, this is another important step in our growth story that further deepens our understanding of the future trends shaping the sector, from building design to sustainability.

"Expanding our offer to the NHS as its partner of choice has never been more vital than it is today. As Apollo's colleagues integrate into Assura, we look forward to working together to continue creating outstanding spaces for health services in our communities."

- ENDS -

For more information, please contact:

Assura plc Jayne Cottam, CFO David Purcell, Head of Investor Relations	Tel: [phone] Email: [e-mail]
Finsbury Gordon Simpson James Thompson	Tel: [phone] Email: [e-mail]

 This announcement contains inside information as defined in Article 7 of the EU Market Abuse Regulation No 596/2014 and has been announced in accordance with the Company's obligations under Article 17 of that Regulation.

Notes to Editors

Assura plc, a constituent of the FTSE 250 and the EPRA* indices, is a UK REIT and long-term investor in and developer of primary care property. The company, headquartered in Warrington, works with GPs, health professionals and the NHS to create outstanding spaces for health services in our communities. At 30 September 2020, Assura's property portfolio was valued at £2,259 million.

Further information is available at www.assuraplc.com

*EPRA is a registered trademark of the European Public Real Estate Association.

Assura plc LEI code: 21380026T19N2Y52XF72

 

END

 

 

ACQUWVARAOUUAUR